Amgen’s Repatha Study Shows Reduced Risk of Heart Attack, Stroke
Amgen’s Repatha Study Shows Reduced Risk of Heart Attack, Stroke
Biography Jonathan D. Rockoff @jonathanrockoff Jonathan.Rockoff@wsj.com Biography Betsy McKay @betswrites Betsy.McKay@wsj.com Researchers found that Amgen Inc.’s new cholesterol-lowering drug Repatha reduced the risk of deaths, heart attacks and strokes by 20% compared with standard treatment with statin drugs, a benefit that the biotech hopes will persuade health insurers to pay the more than $14,500 yearly list price. Yet the risk reduction, although... Most Popular Videos  The Family Behind Viral BBC Video Speaks Out  Dog Takes a Slide Down a Snowy California Mountain  Mount Etna's Latest Explosions Injure 10 People   Teen Scientist Pioneering a New Treatment for Brain Damage    Tony Robbins says this is how to get rich when the market tanks  Most Popular Articles      Opinion: Reach Across the Aisle, Mr. President        When the Children Crashed Dad’s BBC Interview: The Family Speaks        Mike Flynn Worked for Several Russian Companies, Was Paid More Than $50,000        The Secret to a Happy Marriage? Two Master Bedrooms        ‘Beauty and the Beast’ Review: Live Actors, Dead Wrong

Researchers found that Amgen Inc.’s new cholesterol-lowering drug Repatha reduced the risk of deaths, heart attacks and strokes by 20% compared with standard treatment with statin drugs, a benefit that the biotech hopes will persuade health insurers to pay the more than $14,500 yearly list price.

Yet the risk reduction, although...